Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, Raul Aguilar Schall, Catherine Jia, Bryan McColgan, C. Stephen Djedjos, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Zobair Younossi, Andrew J. Muir, Nezam H. Afdhal, Jaime Bosch, Zachary Goodman – 16 April 2019 – Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized.

Ellis Muggleton, Tülin Muggleton – 16 April 2019

Mingyuan Zhang – 16 April 2019

Hee Doo Yang, Hyung Seok Kim, Sang Yean Kim, Min Jeong Na, Gyeongdeok Yang, Jung Woo Eun, Hee Jung Wang, Jae Youn Cheong, Won Sang Park, Suk Woo Nam – 16 April 2019 – Histone deacetylase 6 (HDAC6) uniquely serves as a tumor suppressor in hepatocellular carcinogenesis, but the underlying mechanisms leading to tumor suppression are not fully understood. To identify comprehensive microRNAs (miRNAs) regulated by HDAC6 in hepatocellular carcinogenesis, differential miRNA expression analysis of HDAC6‐transfected Hep3B cells was performed.

Ashish Kumar Vyas, Pooja Negi, Sharda Patra, Jaswinder Singh Maras, Gayatri Ramakrishna, Shiv Kumar Sarin, Nirupma Trehanpati – 16 April 2019 – Vertical transmission of hepatitis B virus (HBV) from the mother to the newborn often results in viral persistence. To understand mechanisms of maternofetal HBV transmission, we studied maternal immunity and peripheral blood mononuclear cell (PBMC) transcriptome in mothers and newborns.

Runping Liu, Xiaojiaoyang Li, Weiwei Zhu, Yanyan Wang, Derrick Zhao, Xuan Wang, Emily C. Gurley, Guang Liang, Weidong Chen, Guanhua Lai, William M. Pandak, H. Robert Lippman, Jasmohan S. Bajaj, Phillip B. Hylemon, Huiping Zhou – 15 April 2019 – Activation of hepatic stellate cells (HSCs) represents the primary driving force to promote the progression of chronic cholestatic liver diseases. We previously reported that cholangiocyte‐derived exosomal long noncoding RNA‐H19 (lncRNA‐H19) plays a critical role in promoting cholestatic liver injury.

Chaopeng Li, Tai Rao, Xiaoping Chen, Zhengsheng Zou, Aiwu Wei, Jinfa Tang, Peng Xiong, Pengyan Li, Jing Jing, Tingting He, Zhaofang Bai, Jiye Yin, Zhirong Tan, Peng Yu, Honghao Zhou, Jiabo Wang, Xiaohe Xiao, Dongsheng Ouyang – 15 April 2019 – Polygonum multiflorum (PM) is a well‐known Chinese herbal medicine that has been reported to induce inflammation‐associated idiosyncratic liver injury. This study aimed to identify the genetic basis of susceptibility to PM‐drug‐induced liver injury (PM‐DILI) and to develop biological markers for predicting the risk of PM‐DILI in humans.

Caroline Ovadia, Alvaro Perdones‐Montero, Konstantina Spagou, Ann Smith, Magali H. Sarafian, Maria Gomez‐Romero, Elena Bellafante, Louise C.D. Clarke, Fouzia Sadiq, Vanya Nikolova, Alice Mitchell, Peter H. Dixon, Natalie Santa‐Pinter, Annika Wahlström, Shadi Abu‐Hayyeh, Julian R.F. Walters, Hanns‐Ulrich Marschall, Elaine Holmes, Julian R. Marchesi, Catherine Williamson – 15 April 2019 – Pregnancy is associated with progressive hypercholanemia, hypercholesterolemia, and hypertriglyceridemia, which can result in metabolic disease in susceptible women.

Chaopeng Li, Tai Rao, Xiaoping Chen, Zhengsheng Zou, Aiwu Wei, Jinfa Tang, Peng Xiong, Pengyan Li, Jing Jing, Tingting He, Zhaofang Bai, Jiye Yin, Zhirong Tan, Peng Yu, Honghao Zhou, Jiabo Wang, Xiaohe Xiao, Dongsheng Ouyang – 15 April 2019 – Polygonum multiflorum (PM) is a well‐known Chinese herbal medicine that has been reported to induce inflammation‐associated idiosyncratic liver injury. This study aimed to identify the genetic basis of susceptibility to PM‐drug‐induced liver injury (PM‐DILI) and to develop biological markers for predicting the risk of PM‐DILI in humans.

Hajime Matsushima, Masato Fujiki, Kazunari Sasaki, Daniel M. Rotroff, Mark Sands, Maria Del Pilar Bayona Molano, Federico Aucejo, Teresa Diago Uso, Bijan Eghtesad, Charles Miller, Cristiano Quintini, Koji Hashimoto – 13 April 2019 – The hepatic venous pressure gradient (HVPG) measurement is known to correlate with the severity of portal hypertension in patients with liver cirrhosis.